INTRODUCTION {#s1}
============

Worldwide, lung cancer is one of the most common cancers and the leading cause of cancer-related mortality among men, and the fourth leading cause of cancer morbidity and the second leading cause of cancer mortality among women \[[@R1], [@R2]\]. In China, lung cancer ranks first among the causes of cancer-related death \[[@R3]\]. Despite improvement in multimodal therapies, the 5-year survival rate for lung cancer is less than 10%. A major reason for this outcome is that a large proportion of lung cancer patients are diagnosed at advanced stages. The definitive mechanism of lung cancer is not fully understood. Evidence suggests that lung cancer is a multifactorial disease caused by genetic and environmental interactions \[[@R4]--[@R6]\].

NAD(P)H: quinone oxidoreductase (NQO1), formerly called DT-diaphorase, is a flavoenzyme associated with carcinogen metabolism \[[@R7]\]. As a two-electron reductase, the NQO1 protein can detoxify highly toxic quinones to less toxic hydroquinone analogues. NQO1 also acts as an antioxidant enzyme *in vivo*. By maintaining antioxidant forms of ubiquinone and reducing the endogenous quinones, NQO1 protects cells from oxidative damage \[[@R8]\]. Research has demonstrated that NQO1 can regulate tumor suppressor gene p53 activity, and thus influence cancer cell life \[[@R9]\]. The human *NQO1* gene, consisting of 6 exons and 5 introns, is located on chromosome 16q22. Numerous single nucleotide polymorphisms (SNPs) of the *NQO1* gene have been identified, but the most frequently studied SNP is *NQO1* C609T \[[@R10]--[@R12]\]. *NQO1* C609T (rs1800566, Pro187Ser) polymorphism is a C-to-T allele base-pair mutation in exon 6 (position 609) of the *NQO1* gene. Such a gene mutation changes the encoded protein from a proline to a serine at position 187. This Pro187Ser mutated protein shows a reduced quinine reductase activity when compared with the wild-type protein \[[@R13]\].

Epidemiological studies have assessed the correlation between the *NQO1* C609T polymorphism and lung cancer risk, but conflicting conclusions remain. In addition, several meta-analyses have been performed to reach a consensus but failed. To clarify the current uncertainty, we performed this comprehensive updated meta-analysis by incorporating all available literature.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

In the initial search stage, 81 potentially relevant published records were obtained. Through literature screening and abstracts reading, 38 articles were selected. We excluded 13 of those articles for the following reasons: 3 articles were case only research \[[@R14]--[@R16]\]; 1 article was duplicative \[[@R17]\], and 8 articles were meta-analyses \[[@R18]--[@R25]\]. However, 3 additional articles were identified from the references of the retrieval articles \[[@R26]--[@R28]\]. The workflow of the study selection process is shown in Figure [1](#F1){ref-type="fig"}. As a result, 37 studies (29 publications \[[@R21], [@R27]--54\]) with 8493 cases and 10,999 controls were used in the investigation (Table [1](#T1){ref-type="table"}). Among the studies, 16 focused on Asians, 14 focused on Caucasians, 4 focused on African-Americans, 1 focused on Hawaiians, 1 focused on Hispanics, and 1 focused on a mixed population; 17 studies were hospital-based designs, 19 were population-based designs, and 1 was a mixed-based design. Of these studies, 23 were considered low quality (quality score ≤ 9), and 14 were considered high quality (quality score \> 9). The control genotype frequencies in agreement with the Hardy-Weinberg equilibrium (HWE) were observed in 28 studies, but were not available in 9 studies.

![The main flowchart of this work](oncotarget-08-102301-g001){#F1}

###### The baseline characteristics of all qualified studies in this meta-analysis

  Name          Year   Country        Ethnicity          Control Source   Genotype method   Language   Case   Control   HWE   Score                                     
  ------------- ------ -------------- ------------------ ---------------- ----------------- ---------- ------ --------- ----- ------- ----- ------ ----- ------ ------- ----
  Wiencke       1997   USA            Caucasian          PB               PCR               English    29     32        61    52      109   161    ---   10             
  Wiencke       1997   USA            African-American   PB               PCR               English    77     39        116   83      53    136    ---   10             
  Chen          1999   USA (Hawaii)   Asian              PB               PCR-RFLP          English    54     48        7     109     64    78     25    167    0.877   10
  Chen          1999   USA (Hawaii)   Caucasian          PB               PCR-RFLP          English    81     49        5     135     105   62     4     171    0.137   10
  Chen          1999   USA (Hawaii)   Hawaiian           PB               PCR-RFLP          English    61     18        4     83      60    39     3     102    0.258   10
  Lin           2000   China          Asian              HB               PCR-RFLP          Chinese    12     63        20    95      41    73     22    136    0.268   3
  Yin           2001   China          Asian              HB               PCR-CTPP          English    28     39        17    84      26    41     17    84     0.909   6
  Xu            2001   USA            Caucasian          HB               PCR-RFLP          English    513    246       21    780     715   341    40    1096   0.933   6
  Xu            2001   USA            Mixed              HB               PCR-RFLP          English    18     14        2     34      20    6      1     27     0.534   7
  Lewis         2001   UK             Caucasian          HB               PCR               English    56     24        2     82      111   32     2     145    0.858   4
  Benhamou      2001   France         Caucasian          HB               PCR-RFLP          English    85     55        10    150     105   62     5     172    0.243   10
  Sunaga        2002   Japan          Asian              HB               PCR-RFLP          English    83     93        22    198     52    77     23    152    0.526   6
  Hamajima      2002   Japan          Asian              HB               PCR-CTPP          English    87     71        34    192     240   286    114   640    0.076   6
  Lin           2003   China          Asian              HB               PCR               English    57     141       198   95      237   332    ---   9              
  Yin           2003   China          Asian              PB               PCR               Chinese    26     41        17    84      28    39     17    84     0.613   4
  Lan           2004   China          Asian              PB               PCR               English    37     57        25    119     32    54     23    109    0.980   8
  Liang         2004   China          Asian              HB               PCR-RFLP          Chinese    37     79        36    152     53    71     28    152    0.624   7
  Alexandrie    2004   Sweden         Caucasian          HB               AS-PCR            English    345    168       11    524     368   153    9     530    0.124   7
  Sorensen      2005   Denmark        Caucasian          PB               TaqMan            English    162    83        9     254     176   80     11    267    0.618   10
  Saldivar      2005   USA            Caucasian          PB               PCR-RFLP          English    454    205       24    683     480   186    17    683    0.839   11
  Saldivar      2005   USA            Hispanics          PB               PCR-RFLP          English    15     17        4     36      15    14     7     36     0.275   8
  Saldivar      2005   USA            African-American   PB               PCR-RFLP          English    67     33        7     107     69    35     3     107    0.563   9
  Skuladottir   2005   Denmark        Caucasians         Mixed            PCR-RFLP          English    108    45        153   227     119   346    ---   6              
  Chan          2005   China          Asian              HB               PCR-RFLP          English    25     37        13    75      45    83     34    162    0.708   5
  Bock          2005   USA            Caucasian          PB               TaqMan            English    93     37        130   87      57    144    ---   7              
  Bock          2005   USA            African-American   PB               TaqMan            English    21     10        31    21      8     29     ---   7              
  Lawson        2005   Finland        Caucasian          PB               PCR               English    244    109       353   243     117   360    ---   10             
  Demirkan      2005   Turkey         Caucasian          PB               PCR               English    47     34        7     88      80    34     3     117    0.785   4
  Yang          2007   Korea          Asian              HB               TaqMan            English    110    158       46    314     120   166    61    347    0.784   10
  Eom           2009   Korea          Asian              HB               PCR-RFLP          English    122    265       387   148     239   387    ---   9              
  Cote          2009   USA            Caucasian          PB               TaqMan            English    271    97        19    387     271   119    15    405    0.668   11
  Cote          2009   USA            African-American   PB               TaqMan            English    77     32        4     113     79    36     6     121    0.478   10
  Su            2009   China          Asian              PB               PCR-RFLP          Chinese    102    199       95    396     139   244    82    465    0.158   8
  Timofeeva     2010   Germany        Caucasian          PB               MALDI-TOF MS      English    429    188       617   856     411   1267   \-    10             
  Guo           2012   China          Asian              HB               PCR-LDR           English    187    327       168   682     171   282    144   597    0.192   8
  Tian          2014   China          Asian              HB               PCR               English    88     171       132   391     215   307    141   663    0.109   10
  Masroor       2015   India          Asian              HB               AS-PCR            English    45     48        7     100     71    26     3     100    0.743   6

HB, hospital based; PB, population based; PCR, polymerase chain reaction; AS-PCR, Allele specific-PCR; PCR-RFLP, PCR-restriction fragment length polymorphism; MALDI-TOF MS, Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry; HWE, Hardy-Weinberg equilibrium.

Meta-analysis results {#s2_2}
---------------------

The calculated results of the meta-analysis are shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. Overall, no significant correlation between the *NQO1* C609T polymorphism and lung cancer risk was observed in any of the genetic models (TT vs. CC: OR = 0.91, 95% CI = 0.74--1.12; CT vs. CC: OR = 1.08, 95% CI = 0.98--1.22; TT vs. CT+CC: OR = 1.13, 95% CI = 0.97--1.33; T vs. C: OR = 1.09, 95% CI = 0.99--1.20; and CT+TT vs. CC: OR = 1.04, 95% CI = 0.94--1.16).

![Forest plot for the correlation between the *NQO1* C609T polymorphism and lung cancer susceptibility\
under the allele comparison model. The horizontal lines represent the study-specific ORs and 95% CIs. The diamond represents the pooled results of OR and 95% CI.](oncotarget-08-102301-g002){#F2}

###### Meta-analysis of the correlation between NQO1 C609T polymorphism and lung cancer risk

  Variables             No. of   Homozygous                     Heterozygous                Recessive                   Allele                         No. of   Dominant            
  --------------------- -------- ------------------- ---------- ------------------- ------- ------------------- ------- ------------------- ---------- -------- ------------------- ----------
  All                   28       0.91 (0.74--1.12)   \< 0.001   1.08 (0.96--1.21)   0.003   1.13 (0.97--1.33)   0.039   1.09 (0.99--1.20)   \< 0.001   37       1.04 (0.94--1.16)   \< 0.001
  Ethnicity                                                                                                                                                                         
   Asian                14       0.82 (0.62--1.09)   \< 0.001   1.10 (0.91--1.34)   0.001   1.09 (0.88--1.34)   0.005   1.08 (0.93--1.26)   \< 0.001   16       1.13 (0.94--1.36)   \< 0.001
   Caucasian            9        1.08 (0.77--1.51)   0.232      1.08 (0.97--1.20)   0.469   1.20 (0.90--1.59)   0.422   1.11 (0.99--1.24)   0.205      14       1.00 (0.89--1.13)   0.048
   African              2        1.22 (0.36--4.15)   0.198      0.94 (0.63--1.41)   0.880   1.28 (0.38--4.29)   0.199   1.01 (0.73--1.41)   0.355      4        0.93 (0.69--1.25)   0.809
  Hawaiian              1        1.33 (0.29--6.21)   ---        0.45 (0.23--0.88)   ---     1.67 (0.36--7.69)   ---     0.66 (0.38--1.12)   ---        1        0.52 (0.28--0.96)   ---
  Hispanics             1        0.57 (0.14--2.37)   ---        1.21 (0.44--3.32)           0.52 (0.14--1.95)   ---     0.84 (0.42--1.65)   ---        1        1.00 (0.39--2.55)   ---
   Mixed                1        2.00 (0.17--23.9)   ---        2.59 (0.82--8.18)   ---     1.63 (0.14--18.9)   ---     2.07 (0.82--5.22)   ---        1        2.54 (0.85--7.58)   ---
  Source of control                                                                                                                                                                 
   PB                   13       1.05 (0.82--1.36)   0.320      1.00 (0.87--1.15)   0.274   1.16 (0.90--1.50)   0.247   1.03 (0.91--1.17)   0.043      19       0.95 (0.84--1.07)   0.067
   HB                   15       0.85 (0.74--1.12)   \< 0.001   1.17 (0.98--1.38)   0.001   1.12 (0.91--1.38)   0.025   1.14 (0.99--1.32)   \< 0.001   17       1.19 (1.01--1.40)   \< 0.001
  Quality score                                                                                                                                                                     
   \> 9                 10       0.93 (0.71--1.22)   0.186      1.00 (0.86--1.17)   0.111   1.16 (0.81--1.67)   0.008   1.02 (0.85--1.22)   \< 0.001   14       0.96 (0.83--1.11)   0.005
   ≤ 9                  18       0.91 (0.74--1.12)   \< 0.001   1.15 (0.98--1.36)   0.004   1.10 (0.97--1.33)   0.496   1.12 (1.00--1.20)   0.001      23       1.12 (0.97--1.30)   \< 0.001
  Smoking status                                                                                                                                                                    
   Ever                 6        1.11 (0.79--1.56)   0.113      1.09 (0.94--1.26)   0.511   1.09 (0.78--1.53)   0.225   1.08 (0.91--1.31)   0.088      14       1.04 (0.94--1.15)   0.283
   Never                4        0.91 (0.48--1.74)   0.276      1.11 (0.79--1.57)   0.292   0.97 (0.53--1.76)   0.396   1.02 (0.69--1.51)   0.099      11       1.03 (0.82--1.28)   0.505
  Lung cancer subtype                                                                                                                                                               
   Non-small cell       10       1.34 (0.90--1.99)   0.002      1.21 (0.99--1.48)   0.031   1.26 (0.94--1.71)   0.025   1.22 (1.00--1.48)   \< 0.001   13       1.16 (0.96--1.40)   0.001
   Small cell           3        2.57 (1.24--5.32)   0.730      1.24 (0.93--1.65)   0.481   2.38 (1.16--4.88)   0.813   1.35 (1.06--1.71)   0.358      3        1.33 (1.01--1.75)   0.388

Het, heterogeneity; HB, hospital based; PB, population based; NA, not available.

Further subgroup analysis by ethnicity, control source, quality score, and smoking status still did not yield a significant association, except for the heterozygous model and dominant model in the Hawaiian subgroup (CT vs. CC: OR = 0.45, 95% CI = 0.23--0.88; CT+TT vs. CC: OR = 0.52, 95% CI = 0.28--0.96) and the allele model in the quality score ≤ 9 subgroup (T vs. C: OR = 1.12, 95% CI = 1.00--1.20). In the subgroup analysis by lung cancer subtype, statistically significant increased risks were found among non-small cell lung cancer for T vs. C (OR = 1.22, 95% CI = 1.00--1.48) and small cell lung cancer for TT vs. CC (OR = 2.57, 95% CI = 1.24--5.32), TT vs. CT+CC (OR = 2.38, 95% CI = 1.16--4.88), T vs. C (OR = 1.35, 95% CI = 1.06--1.71) and CT+TT vs. CC (OR = 1.33, 95% CI = 1.01--1.75).

Heterogeneity and sensitivity analysis {#s2_3}
--------------------------------------

Before calculating the ORs and 95% CIs, we used the *Q*-test and the I-squared statistics to test between-study heterogeneity. In the pooled analysis, significant heterogeneity exists among all five genetic models (*P* \< 0.001, I^2^ = 55.2% for Homozygous, *P* = 0.003, I^2^ = 47.2% for Heterozygous, *P* = 0.039, I^2^ = 34.5% for Recessive, *P* \< 0.001, I^2^ = 63.2% for Allele and *P* \< 0.001, I^2^ = 57.0% for Dominant genetic models). Thus, the random-effect model was used to generate wider CIs. Moreover, we adopted a sequential leave-one-out sensitivity analysis to assess the influence of a single study on the combined ORs. After omitting each study, no substantial changes in ORs were observed, which suggested the robust and reliability of this meta-analysis (Figure [3](#F3){ref-type="fig"}).

![Sensitivity analysis of the association between *NQO1* C609T and lung cancer susceptibility under the allele comparison model\
Each point represents the recalculated OR after deleting a separate study.](oncotarget-08-102301-g003){#F3}

Publication bias {#s2_4}
----------------

No evidence of obvious asymmetry in Begg\'s funnel plots was identified by visual observation (Figure [4](#F4){ref-type="fig"}). In addition, Egger\'s test also indicated that no publication bias was shown among the studies (TT vs. CC: *P* = 0.48; CT vs. CC: *P* = 0.45; TT vs. CT+CC: *P* = 0.76; T vs. C: *P* = 0.93; and CT+TT vs. CC: *P* = 0.79).

![Funnel plot analysis to detect publication bias for *N*QO1 C609T polymorphism under the allele comparison model\
Each point represents a separate study.](oncotarget-08-102301-g004){#F4}

Trial sequential analysis {#s2_5}
-------------------------

The TSA showed that the cumulative Z-curve failed to cross the trial monitoring boundary before reaching the required information size, suggesting that more trials are needed to further verify the conclusions (Figure [5](#F5){ref-type="fig"}).

![The required information size to demonstrate the correlation between *NQO1* C609T polymorphism with lung cancer susceptibility\
The solid blue line is the cumulative Z-curve. The dashed inward-sloping line to the left represents the trial sequential monitoring boundaries.](oncotarget-08-102301-g005){#F5}

DISCUSSION {#s3}
==========

In this meta-analysis, we investigated the role of *NQO1* C609T polymorphism in lung cancer susceptibility. The obtained results suggest that no significant relation exists. To date, this meta-analysis includes the largest samples used in the investigation of the function of *NQO1* C609T in lung cancer susceptibility.

Numerous studies have investigated the activity of the *NQO1* gene C609T polymorphism in lung cancer risk. In 1999, Chen et al. \[[@R30]\] claimed that *NQO1* C609T polymorphism correlates with decreased lung cancer risk in Japanese. In another study conducted in England that consists of 82 lung cancer patients and 145 controls, Lewis et al. \[[@R31]\] failed to detect any correlation between *NQO1* C609T and lung cancer risk. However, Masroor et al. \[[@R32]\] reported that the *NQO1* 609TT genotype could increase the risk of lung cancer in an Indian population of 100 lung cancer cases and 100 healthy controls. Several meta-analyses have been performed to obtain a clear correlation between *NQO1* C609T and lung cancer risk. In a pilot meta-analysis conducted by Kiyohara et al. \[[@R22]\], only 10 studies were included, consisting of 2746 cases and 3902 controls. They found that the Ser allele is a protective factor against lung cancer in Asians, but not in Caucasians. In a meta-analysis that included 25 articles (32 studies) with 7522 cases and 9291 controls, Lou et al. \[[@R25]\] failed to observe any correlation between *NQO1* C609T polymorphism and lung cancer risk overall in African-Americans, East Asians, or Hispanics. However, the results suggested that *NQO1* C609T polymorphism might correlate with lung cancer risk in Caucasians.

This updated and comprehensive meta-analysis was performed to better elucidate the correlation between *NQO1* C609T polymorphism and lung cancer risk. However, we failed to observe any significant relation between *NQO1* C609T and lung cancer risk in the pooled analysis in any of the five genetic models. Subgroup analysis by ethnicity suggested that the T allele might be a protective factor in Hawaiians (CT vs. CC: OR = 0.45, 95% CI = 0.23--0.88; CT+TT vs. CC: OR = 0.52, 95% CI = 0.28--0.96). In this Hawaiian subgroup, only one study, with 83 cases and 102 controls was included, which limits the strength of this result. Thus, more case-control studies in Hawaiians are needed to elucidate the role of C609T polymorphism in lung cancer risk. In another subgroup stratified by quality score, we did not detect any correlation between *NQO1* C609T and lung cancer risk, yet the T allele acts as a risk factor for lung cancer in low-quality studies under the allele model (T vs. C: OR = 1.12, 95% CI = 1.00--1.20). The insufficient statistical power of the relatively low-quality studies should be also considered. It is possible that such insufficient statistical power might result in false positive results. When we stratified the analysis on the basis of lung cancer subtype, an increased risk of the *NQO1* C609T polymorphism on small cell lung cancer was observed. Previous pooled analyses have demonstrated that small cell lung cancer was more frequently observed in patients exposed to tobacco smoke \[[@R29]\]. The *NQO1* C609T polymorphism might result in failure of NQO1 protein to detoxify highly toxic quinones, and thus have some consequences for smoking-related small cell lung cancer risk.

In this meta-analysis, we adopted many measurements to be certain of the credibility of our conclusion. First, we incorporated all eligible studies not only written in English but also written in Chinese to expand the included sample numbers. Then the sensitivity analysis and the publication bias were assessed according to the Cochrane protocol. The sensitivity analysis indicated that the results were robust, and Funnel plots suggested that no obvious publication bias was observed. The TSA was also used to test the conclusion reliability of this meta-analysis. The Z-curve failed to cross the trial monitoring boundary before reaching the required information size. Thus, more studies are needed to confirm or refute this finding. However, the limitations must be pointed out when the results of this meta-analysis are interpreted. First, we found that most of the comparisons show significant between-study heterogeneity, which might reduce the validity of the conclusion. Second, the strength of correlation was obtained by use of unadjusted estimates. Adjustment analysis was absent because of the lack of original data, such as environmental factors, age, drinking status, and gene-environment interactions, which restrains further analysis for risk factors. Nearly all the included case-control studies were conducted among Asians and Caucasians. Other ethnicities, such as Africans, were not studied. Additional studies are needed to confirm such conclusions from other ethnicities, especially Africans. Publication bias and language bias still exist, because only published studies and only the studies written in English or Chinese are included.

The current meta-analysis provides evidence that *NQO1* C609T polymorphism is not correlated with lung cancer risk, from the perspective of the former case-control studies. Further high-quality investigations with more detailed environmental exposure information and larger sample sizes are warranted to confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

We performed a comprehensive literature search of PubMed and EMBASE by adopting the combination of the following phrases: "polymorphism or single nucleotide polymorphism or SNP or variant" and "*NQO1* or quinone reductase or quinone oxidoreductase or DT-diaphorase or DTD," and "lung cancer or lung neoplasm or lung carcinoma." To enlarge the included studies, we also searched China National Knowledge Infrastructure (CNKI) and Wanfang databases using the above phrases in Chinese. In addition, eligible studies in the references of retrieved articles were also screened. The literature search was performed before April 2017 without any language publication restrictions. If an article contained two or more ethnic subpopulations, they were treated as separate studies. Only the largest study was included if two or more articles contained overlapping data. The designation and writing of this meta-analysis were under the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-analyses.

Eligibility criteria {#s4_2}
--------------------

All the included articles in this meta-analysis met the following criteria: (1) contained unrelated case-control studies, (2) evaluated the correlation of *NQO1* C609T polymorphism with lung cancer risk, (3) contained enough genotype distribution information to calculate ORs and 95% CIs, and (4) *NQO1* C609T genotype frequency in control subjects were in agreement of the Hardy-Weinberg equilibrium (HWE).

Data extraction {#s4_3}
---------------

Authors Jiawen Huang and Huiran Lin screened the articles and extracted data from all eligible studies, respectively. The data include first author\'s surname, publication year, country, ethnicity, the source of control subjects, genotyping methods, quality score, and numbers of cases and controls with CC, CT, and TT genotypes. Conflicting data were resolved by discussion after consensus was reached

Quality assessment {#s4_4}
------------------

The quality of each study was assessed by use of the quality assessment criteria \[[@R30]--[@R32]\]. The evaluation items were as follows: representativeness of case, representativeness of control, ascertainment of cancer, control selection, genotyping examination, HWE, and total sample size. Each study was evaluated on a scale from 0--15. Quality score of studies ranges from 0 to 15 points. Studies with scores ≤ 9 were of low quality, whereas those with scores \> 9 were of high quality. The detail of score of quality assessment was listed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Statistical methods {#s4_5}
-------------------

All five genetic models, homozygous model (TT vs. CC), heterozygous model (CT vs. CC), recessive model (TT vs. CT + CC), dominant model (CT + TT vs. CC), and allele comparison (T vs. C) were adopted to investigate the correlation between *NQO1* C609T polymorphism and lung cancer risk. The strength of such correlation was assessed by calculating ORs with the corresponding 95% CIs. Stratification analyses were also performed by ethnicity, and source of control subjects, quality score, HWE in control subjects, smoking status, and lung cancer subtype. Between-study heterogeneity was analyzed by chi squared-based *Q*-test. When the studies were found to be homogeneous (with *P* \> 0.10 for the *Q*-test), the fixed-effects model (the Mantel-Haenszel method) was used to estimate the pooled OR. Otherwise, the random-effects model (the DerSimonian and Laird method) was adopted. Sensitivity analysis was done by individually removing studies one by one and reanalyzing the pooled risk estimates. Begg\'s funnel plot and Egger\'s linear regression were used to estimate potential publication bias, with that asymmetric plot and a *P*-value \< 0.05, indicating the presence of publication bias. HWE in the control subjects was tested by use of goodness-of-fit chi-squared test. A value of *P* \< 0.05 was considered as departure from HWE. All statistical analyses were completed by STATA Version 11.0 software (Stata Corporation, College Station, TX). All the statistics were two-sided, with significant findings set at a *P*-value of less than 0.05.

Trial sequential analysis {#s4_6}
-------------------------

To avoid the random errors caused by repeated significance testing and dispersed data, we performed the trial sequential analysis (TSA). First, the required information size was evaluated by considering an overall type I error (a) of 5% and type II error (b) of 20%. Then TSA monitoring boundaries were constructed on the basis of required information size as well as risk for type I and type II errors. If the cumulative Z-curve (blue line) crosses a TSA monitoring boundary (red lines) before reaching the required information size, the robustness of evidence might be confirmed and no further trials are necessary. Otherwise, to get a robust conclusion, more trials are needed.
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